The paper describes the development of SPYTACs, a novel synthetic peptide platform designed to treat Alzheimer’s disease through targeted protein degradation. By utilizing the LRP1 receptor, these bifunctional peptides facilitate the transport of toxic amyloid-β proteins to lysosomes for clearance in both the brain and the liver. Research conducted on 5×FAD mice demonstrates that this technology effectively crosses the blood-brain barrier to reduce plaque buildup and improve cognitive performance. Notably, the study highlights that SPYTACs achieve these therapeutic results with significantly fewer side effects, such as brain inflammation and microhemorrhage, compared to traditional antibody-based immunotherapies. Because the system is modular and programmable, it offers a versatile framework for addressing various other conditions driven by harmful extracellular proteins.

References:

• Teng F, Liu J, Cui T, et al. Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs[J]. Cell, 2026.